A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

3,100

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions

COVID-19

Interventions

BIOLOGICAL

Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

BIOLOGICAL

Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)

boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)

All Listed Sponsors

lead

WestVac Biopharma Co., Ltd.

INDUSTRY